<DOC>
	<DOCNO>NCT02513355</DOCNO>
	<brief_summary>Research purpose : Degree continuous intravenous pump Endostar ( human recombinant endostatin ) combination chemotherapy regimens include cisplatin two medicine first-line treatment advance non-small cell lung cancer ( exception EGFR/ALK mutation ) efficacy safety .</brief_summary>
	<brief_title>Endostar Treatment Advanced Non-small Cell Lung Cancer Multi-center Clinical Research</brief_title>
	<detailed_description>1.Research purpose : Degree continuous intravenous pump Endostar ( human recombinant endostatin ) combination chemotherapy regimens include cisplatin two medicine first-line treatment advance non-small cell lung cancer ( exception EGFR/ALK mutation ) efficacy safety . 2.1 main objective : PFS 2.2 secondary goal : 2.2 . 1 ORR , DCR OS 2.2 . 2 quality life 3 . The study design 3.1 research nature This single arm , multicenter clinical study , expect total 100 patient group . Hierarchical factor include : tumor staging ( Ⅲ B v Ⅳ ) , ECOG score ( 0 v 1 ) , gender ( male v female ) . 3.2 research center research Proposed taizhou people 's hospital medical association jiangsu province tumor chemotherapy biological branch lung cancer group lead several large medium-sized hospital province malignant tumor treatment relate department participate , accordance unify test plan research .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Histologic confirmation cytology patient undergo single sputum cytology diagnosis patient nonsmall cell lung cancer ; accord new IASLC2009 lung cancer TNM stag judge preious untreated stage IIIB IV nonsmall cell lung cancer ( exception EGFR/ALK mutation type ) ; must least one accord RRECIST version 1.1 standard judgment evaluate lesion ( least 10 mm , maximum diameter spiral CT plain CT long diameter least 20 mm ) ; male female , age 18 75 year old less ; ECOG PS 0 ~ 1 minute ; expect survive period 3 month , enough blood function : absolute neutrophil count ( ANC ) 2 x 109 / L platelet count 100 x 109 / L high acuity 9 g/dL hemoglobin ; Liver function enough : upper limit total bilirubin acuity normal ( ULN ) ; AST ALT acuities 2.5 time upper limit normal ( ULN ) ; Alkaline phosphatase 5 time upper limit normal less ( ULN ) ; enough renal function , serum creatinine less normal limit ( ULN ) calculate creatinine clearance 60 mL/min . basic normal ecg , body heal wound ; always receive antitumor drug therapy , always non metastatic tumor adjuvant neoadjuvant chemotherapy , study treatment end six month begin ; ever surgery patient , request study treatment begin 4 week , patient recover ; complete uterus female group within 28 day study must negative pregnancy test result ( except amenorrhea 24 month ) . If pregnancy test first time 7 day , need urine pregnancy test validation ( within 7 day first delivery ) . prior biological agent , especially e. coli genetically engineer product without severe allergic reaction ; sign informed consent . Exclusion criterion pregnancy , nurse mother , fertility woman use contraception ; exist serious acute infection , control ; Or fester sex chronic infection , wound delay ; original serious heart disease , include : high risk congestive heart failure , unable control arrhythmia , unstable angina , myocardial infarction , severe valvular heart disease , resistant hypertension ; easy control nerve , mental illness mental disorder , compliance poor , ca n't cooperate account response treatment ; Primary brain tumor CNS metastases illness get control , obvious symptom cranial hypertension nerve spirit ; bleed tendency ; researcher believe patient participate test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Non-small cell lung cancer , Endostar</keyword>
</DOC>